|
1
|
Cao M, Li H, Sun D and Chen W: Cancer
burden of major cancers in China: A need for sustainable actions.
Cancer Commun (Lond). 40:205–210. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brooks RA, Fleming GF, Lastra RR, Lee NK,
Moroney JW, Son CH, Tatebe K and Veneris JL: Current
recommendations and recent progress in endometrial cancer. CA
Cancer J Clin. 69:258–279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Travaglino A, Raffone A, Saccone G, De
Luca C, Mollo A, Mascolo M, De Placido G, Insabato L and Zullo F:
Immunohistochemical nuclear expression of β-catenin as a surrogate
of CTNNB1 exon 3 mutation in endometrial cancer. Am J Clin Pathol.
151:529–538. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial
cancer: Diagnosis, treatment and follow-up. Radiother Oncol.
117:559–581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brassard L and Bessette P: Value of
gynecological cytology and CA 125 level for the prediction of
extrauterine malignancy in endometrial cancer. J Obstet Gynaecol
Can. 34:657–663. 2012.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roelofsen T, Mingel M, Hendriks JC, Samlal
RA, Snijders MP, Aalders AL, Bulten J, van Ham MA and Massuger LF:
Preoperative CA-125 predicts extra-uterine disease and survival in
uterine papillary serous carcinoma patients. Int J Biol Markers.
27:e263–e271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yildiz A, Yetimalar H, Kasap B, Aydin C,
Tatar S, Soylu F and Yildiz FS: Preoperative serum CA 125 level in
the prediction of the stage of disease in endometrial carcinoma.
Eur J Obstet Gynecol Reprod Biol. 164:191–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baser E, Gungor T, Togrul C, Turkoglu O
and Celen S: Preoperative prediction of poor prognostic parameters
and adjuvant treatment in women with pure endometrioid type
endometrial cancer: What is the significance of tumor markers? Eur
J Gynaecol Oncol. 35:513–518. 2014.PubMed/NCBI
|
|
12
|
Hashiguchi Y, Kasai M, Fukuda T, Ichimura
T, Yasui T and Sumi T: Serum carcinoembryonic antigen as a tumour
marker in patients with endometrial cancer. Curr Oncol.
23:e439–e442. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bian J, Sun X, Li B and Ming L: Clinical
significance of serum HE4, CA125, CA724, and CA19-9 in patients
with endometrial cancer. Technol Cancer Res Treat. 16:435–439.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arakawa N, Miyagi E, Nomura A, Morita E,
Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome-based
identification of TFPI2, a novel serum biomarker for detection of
ovarian clear cell adenocarcinoma. J Proteome Res. 12:4340–4350.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyagi Y, Koshikawa N, Yasumitsu H, Miyagi
E, Hirahara F, Aoki I, Umeda M and Miyazaki K: cDNA cloning and
mRNA expression of a serine proteinase inhibitor secreted by cancer
cells: Identification as placental protein 5 and tissue factor
pathway inhibitor-2. J Biochem. 116:939–942. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arakawa N, Kobayashi H, Yonemoto N,
Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y,
Hirahara F, et al: Clinical significance of tissue factor pathway
inhibitor 2, a serum biomarker candidate for ovarian clear cell
carcinoma. PLoS One. 11:e01656092016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wojtukiewicz MZ, Sierko E, Zimnoch L,
Kozlowski L and Kisiel W: Immunohistochemical localization of
tissue factor pathway inhibitor-2 in human tumor tissue. Thromb
Haemost. 90:140–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawaguchi R, Maehana T, Sugimoto S,
Kawahara N, Iwai K, Yamada Y and Kimura F: Immunohistochemical
analysis of the tissue factor pathway inhibitor-2 in endometrial
clear cell carcinoma: A single-center retrospective study. Int J
Gynecol Pathol. May 31–2023.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chao A, Tang YH, Lai CH, Chang CJ, Chang
SC, Wu TI, Hsueh S, Wang CJ, Chou HH and Chang TC: Potential of an
age-stratified CA125 cut-off value to improve the prognostic
classification of patients with endometrial cancer. Gynecol Oncol.
129:500–504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pinar Cilesiz Goksedef B, Gorgen H, Baran
SY, Api M and Cetin A: Preoperative serum CA 125 level as a
predictor for metastasis and survival in endometrioid endometrial
cancer. J Obstet Gynaecol Can. 33:844–850. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yilmaz Baran Ş, Alemdaroğlu S, Doğan
Durdağ G, Yüksel Şimşek S, Bolat F, Köse F and Çelik H: What is the
predictive value of preoperative CA 125 level on the survival rate
of type 1 endometrial cancer? J Med Sci. 51:335–341.
2021.PubMed/NCBI
|
|
22
|
Lo SS, Cheng DK, Ng TY, Wong LC and Ngan
HY: Prognostic significance of tumour markers in endometrial
cancer. Tumour Biol. 18:241–249. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alagoz T, Buller RE, Berman M, Anderson B,
Manetta A and DiSaia P: What is a normal CA125 level? Gynecol
Oncol. 53:93–97. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kurihara T, Mizunuma H, Obara M, Andoh K,
Ibuki Y and Nishimura T: Determination of a normal level of serum
CA125 in postmenopausal women as a tool for preoperative evaluation
and postoperative surveillance of endometrial carcinoma. Gynecol
Oncol. 69:192–196. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brennan DJ, Hackethal A, Metcalf AM,
Coward J, Ferguson K, Oehler MK, Quinn MA, Janda M, Leung Y,
Freemantle M, et al: Serum HE4 as a prognostic marker in
endometrial cancer-a population based study. Gynecol Oncol.
132:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Abbink K, Zusterzeel PL, Geurts-Moespot
AJ, Herwaarden AEV, Pijnenborg JM, Sweep FC and Massuger LF: HE4 is
superior to CA125 in the detection of recurrent disease in
high-risk endometrial cancer patients. Tumour Biol.
40:10104283187571032018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ota Y, Koizume S, Nakamura Y, Yoshihara M,
Takahashi T, Sato S, Myoba S, Ohtake N, Kato H, Yokose T, et al:
Tissue factor pathway inhibitor-2 is specifically expressed in
ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and
extracellular matrix. Oncol Rep. 45:1023–1032. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chand HS, Foster DC and Kisiel W:
Structure, function and biology of tissue factor pathway
inhibitor-2. Thromb Haemost. 94:1122–1130. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kobayashi H, Yamada Y, Kawaguchi R, Ootake
N, Myoba S and Kimura F: Tissue factor pathway inhibitor 2: A
potential diagnostic marker for discriminating benign from
malignant ovarian tumors. J Obstet Gynaecol Res. 48:2442–2451.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Y, Chi S, Zhou X, Zhao R, Xiao C and
Wang H: Prognostic value of distant metastatic sites in stage IV
endometrial cancer: A SEER database study of 2948 women. Int J
Gynaecol Obstet. 149:16–23. 2020. View Article : Google Scholar : PubMed/NCBI
|
